Home 2018-02-02T05:37:12+00:00


Aragen’s RapTr™ Cell Line Development services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process that delivers high titers at every stage from Discovery to the Clinic.

Molecular Med Tri-Con
February 11-16, 2018 |
San Francisco, CA

Press Releases

Aragen Bioscience Announces AAALAC Accreditation

RapTr Cell Line Development Services Introduced